July 24, 2023

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

CLOSURE

HEAD & NECK

NRG-HN001: Accrual Closure: July 24, 2023 (posted on CTSU)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BRAIN

NRG-BN005: A patient Study Web Page is available on the NRG website and an updated patient brochure is posted on CTSU

3. BREAST

NSABP B-51/RTOG 1304: Call for submission of data and supporting documentation. Please see the memorandum, dated June 27, 2023, posted on CTSU for additional information.

4. GASTROINTESTINAL

NRG-GI002: Call for submission of data and supporting documentation. Please refer to the memorandum, dated July 10, 2023, posted on the CTSU website for additional information.

NRG-GI003: A patient Study Web Page is available on the NRG website and an updated patient brochure is posted on the CTSU website.

5. GYNECOLOGIC

GOG-0210: Reminder: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.

NRG-GY012 and NRG-GY023: Reminder: BLOOD PRESSURE CUFF SUPPLY IS VERY LIMITED - Please be advised that VWR has a very limited supply of blood pressure cuffs at present. Please check your supplies on site for any overlooked cuffs prior to ordering. Thank you for your cooperation. 

Printing Biospecimen Transmittal PDFs on GYN Trials

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

6. HEAD & NECK

NRG-HN008: Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important. 

7. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, August 9, 2023.

DRUG SAFETY AND INVESTIGATOR’S BROCHURE (IB) UPDATES

Drug Safety and Investigator’s Brochure updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Online Agent Order Processing (OAOP) website. Log-in using your Identity and Access Management (IAM) username and password credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

REGISTER TODAY! The NRG Oncology Brain Metastasis Trial Webinar: Portfolio Review

NRG Oncology Brain Tumor Committee will be hosting a webinar on brain metastasis trials in the NRG Oncology portfolio. This session will be lead by NRG Brain Tumor Committee Chair, Dr. Minesh Mehta, and will feature presentations on NRG-BN012, CCTG CE.7, NRG-CC009, and NRG-BN009. The webinar will be held on August 4, 2023 from 1-2pm ET. Download the webinar flyer here. Register here.

NRG Oncology Seeks to Fill the Position of Vice-Chair, NRG Oncology NCORP Health Disparities Research Committee

Application Deadline: July 28, 2023

We are seeking nominations for the position of Vice-Chair of the NRG NCORP Health Disparities Research (HDR) committee. The successful candidate will work closely with the chair, Dr. Jennifer Wenzel and provide support to lead the HDR committee. The overarching goal of NRG HDR is to understand and address health disparities in an effort to reduce the unequal burden of cancer in the United States. Candidates for this position should have a track record of funding and/or publications in successful methods to improve access to clinical trials in historically underserved populations. The candidate should demonstrate a passion to elevate and nurture cancer equity, ensuring that NRG Oncology trials prioritize health and cancer outcomes for all patients, families, and communities. Further, the candidates should have documented achievements in mentorship and a willingness to provide timely consultation to members and liaisons of NRG committees as concepts and protocols are being developed. Read more

NRG Oncology is pleased to report the scientific articles that appeared during the previous week. This publications report includes the link to these article.

JOURNAL ARTICLES

Please note a correction to the “Read more” link for the following manuscript that was originally provided in the July 17, 2023, Broadcast:

Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Consortium NPCA, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. Res Sq [Preprint]. 2023 Apr 21:rs.3.rs-2790858. doi: 10.1056/EVIDoa2300023. PMID: 37131691; PMCID: PMC10153374. Read more.

Lukka HR, Deshmukh S, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M 3rd, Feng FY, Pugh SL, Sandler HM, Kachnic LA. Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul 15;116(4):770-778. doi: 10.1016/j.ijrobp.2022.12.022. Epub 2022 Dec 31. PMID: 36592721. Read more.

Dahl DM, Karrison TG, Michaelson MD, Pham HT, Wu CL, Swanson GP, Shipley WU, Vuky J, Lee RJ, Zietman AL, Souhami L, Chang BK, Deming RL, Ellerton JA, Sandler HM, Rodgers JP, Feng FY, Efstathiou JA. Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation. Eur Urol Oncol. 2023 Jul 11:S2588-9311(23)00115-3. doi: 10.1016/j.euo.2023.05.013. Epub ahead of print. PMID: 37442672. Read more.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Society for Radiation Oncology (ASTRO); Oct 1-4, 2023; Chicago, IL

International Society for Quality-of-Life Research (ISOQOL); Oct 18-21, 2023; Calgary, AB Canada

UPCOMING ABSTRACT SUBMISSION DEADLINES

European Society of Gynaecological Oncology (ESGO); Sep 28-Oct 1, 2023; Istanbul, Turkey; LBA Aug 7, 2023

European Society for Medical Oncology (ESMO) Congress; Oct 20-24, 2023; Madrid, Spain; LBA Sep 14, 2023, 9pm CEST

International Gynecologic Cancer Society (IGCS);Nov 5-7, 2023; Seoul, South Korea; Abstract & Film; TiP LBA, Aug 21, 2023

San Antonio Breast Cancer Symposium (SABCS); Dec 5-9, 2023; LBA Sep 30, 2023, 11:59 PM CT

Society for NeuroOncology (SNO); Nov 15-19, 2023; Vancouver, Canada; LBA Sep 4, 2023, 5:00 PM ET